Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

RET Inhibitor

Selpercatinib, LOXO-292, LY3527723

Phase 3

Medullary Thyroid Cancer
RET Inhibitor Enrolling
Selpercatinib, LOXO-292, LY3527723
NSCLC
RET Inhibitor Enrolling
Selpercatinib, LOXO-292, LY3527723

Phase 2

NSCLC, Medullary Thyroid Cancer, Papillary Thyroid Carcinoma, or Other Advanced Solid Tumors
RET Inhibitor Enrolling
Selpercatinib, LOXO-292, LY3527723
Pediatric Cancer
RET Inhibitor Enrolling
Selpercatinib, LOXO-292, LY3527723

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.